The Company
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Contact
Office
Investors
Media
Svenska
The Company
Promore Pharma in Brief
Vision and Strategy
Market
Team
Board of Directors
Projects
Ropocamptide – Healing of Chronic Wounds
Publications
Investors
Promore Pharma on Nasdaq First North Growth Market
Certified Adviser
The Share
Shareholders
Warrant Programs
Share capital development
Analysts
Financial Reports
Press Releases
Prospectuses
Presentations and Events
Calendar
Subscribe
Corporate Governance
Corporate Governance
General Meeting
General Meetings
Nomination Committee
Nomination Committees
The Board of Directors
Board of Directors
The Management
Management
Remunerations and Remuneration Committee
Auditor and Audit Committee
Articles of Association
Certificate of Registration
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Office
Investors
Media
Media
Press Releases
Imagebank
Promore Pharma in Media
Subscribe
Contact
Erik Magnusson
Chief Financial Officer (CFO)
+46 70 856 52 45
Press Releases
All press releases
Regulatory press releases
Non-regulatory press releases
2019
2023
2022
2021
2020
2018
2017
2016
2015
2013
All years
December 10, 2019
Promore Pharma has finalized recruitment of patients in HEAL LL-37 early
December 2, 2019
Promore Pharma’s rights issue completed
November 22, 2019
Promore Pharma publishes supplementary prospectus in connection with the ongoing rights issue
November 22, 2019
Promore Pharma AB (publ) Interim report January – September 2019
November 12, 2019
Promore Pharma is granted a patent for PXL01 in the US
November 12, 2019
Promore Pharma publishes prospectus in connection with rights issue
October 22, 2019
Report from the Extraordinary Shareholders’ Meeting of Promore Pharma AB held on 22 October 2019
October 21, 2019
Promore Pharma engages ABG Sundal Collier as liquidity provider
October 17, 2019
Nomination Committee Appointed for the Annual General Meeting 2020 in Promore Pharma
October 7, 2019
Notice of Extraordinary Shareholders’ Meeting in Promore Pharma AB (publ)
October 6, 2019
Promore Pharma Rights issue – correction of date
October 4, 2019
Promore Pharma Promore Pharma carries out a rights issue of approximately SEK 75 million, underwritten up to 80 percent, and intends to publish its interim report early
August 28, 2019
Promore Pharma AB (publ) Interim report January – June 2019
August 27, 2019
Promore Pharma is granted a patent for LL-37 in Japan
August 23, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the second quarter 2019
June 20, 2019
Promore Pharma has recruited half of the patients in HEAL LL-37
May 21, 2019
Report from the Annual General Meeting of Promore Pharma AB held on 21 May 2019
May 21, 2019
Promore Pharma AB (publ) Interim report January – March 2019
May 15, 2019
Invitation to Presentation of Promore Pharma’s Interim report for the first quarter 2019
April 16, 2019
Notice of Annual General Meeting in Promore Pharma AB (publ)
February 26, 2019
Promore Pharma AB (publ) Year-end report 2018
February 20, 2019
Invitation to Presentation of Promore Pharma’s Year-end report for 2018
February 1, 2019
Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
January 31, 2019
Subscription price for Promore Pharma’s warrants TO1 determined
